Clinical trials: Epithelioid Hemangioendothelioma (EHE)
Epithelioid Hemangioendothelioma (EHE)
SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma
This is a non-randomized, open label, single arm Phase II trial with a two-stage design with histologically-confirmed metastatic and/or recurrent epithelioid hemangioendothelioma requiring systemic treatment.
- Trial name
- NCT07104331
- Testing
- nab-Sirolimus
- Where
- 6 sites in United States
- Volunteers
- 41 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Mesothelioma, Epithelioid Hemangioendothelioma(EHE)
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in…
- Conditions
- Mesothelioma, Epithelioid Hemangioendothelioma(EHE), Solid Tumor
- Trial name
- NCT06452160
- Testing
- BGC515
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- BridGene Biosciences Inc.
Angiosarcoma, Epithelioid Hemangioendothelioma
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE). -The drug involved in this study is Eribulin
- Trial name
- NCT03331250
- Testing
- Eribulin
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Massachusetts General Hospital
Solid Tumors, Adult, Solid Tumor
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
This is a Phase 1, first-in-human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of IK-930, an oral TEAD inhibitor, administered orally…
- Conditions
- Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM), Epithelioid Hemangioendothelioma (EHE)
- Trial name
- NCT05228015
- Testing
- IK-930, Osimertinib
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 67 people
- Sponsor
- Ikena Oncology